← All trials
NCT04327401
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 13, 2020
- Primary completion
- Aug 30, 2020
- Completion date
- Aug 30, 2020
- First posted
- Mar 31, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital Sirio-LibanesLead sponsor
- Albert Einstein Israelite HospitalCollaborator
- Ache Laboratorios Farmaceuticos S.A.Collaborator
- Hospital Sirio-LibanesSponsor investigator
- Hospital Sirio-LibanesReponsible party - principal investigator
- Hospital do CoracaoCollaborator
- Brazilian Research In Intensive Care NetworkCollaborator
- Federal University of Juiz de ForaOverall official - principal investigator
- Hospital Sirio-LibanesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.